The SEC announced last week that it had filed a complaint against Cassava Sciences, Inc., a “pharmaceutical company with one primary drug ...

On Friday, Cassava Sciences Inc (SAVA) stock saw a decline, ending the day at $28.49 which represents a decrease of $-3.38 or -10.61% from the prior close of $31.87. The stock opened at $28.08 and ...

Enston specifically references eleven ingredients — beans, cassava, coconut and rice among them — which make up the backbone ...

Before market open, Cassava announced that it has reached agreement with the U.S. Securities and Exchange Commission (SEC) to ...

Biopharmaceutical company Cassava Sciences, along with founder Remi Barbier and former Senior Vice President of Neuroscience Lindsay Burns, PhD, will pay more than $40 million to settle allegations ...

Bristol Myers trades higher after the FDA approves an oral medication for schizophrenia in adults, fiscal fourth-quarter ...

Neuroscience-focused biopharmaceutical company Cassava Sciences Inc. and two former executives have agreed to pay over $40 ...

A former Alzheimer's researcher manipulated the results of a Cassava Sciences drug, with the pharmaceutical company and its ...

In this week’s notable new products roundup, Jelly Belly evokes nostalgia through two new collaborations with toy giant ...

Despite the settlement, the Securities and Exchange Commission on Thursday sued Cassava Sciences in the Western District Court of Texas, claiming that the company misled investors regarding the Phase ...

Key Takeaways Cassava Sciences and two former executives agreed to pay more than $40 million in a settlement with the SEC.The ...

What comes next for Pfizer's Oxbryta sickle cell drug —Cassava Sciences' SEC charges —Bristol's new schizophrenia treatment ...